Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 340
- Registration Number
- NCT01167725
- Locations
- 🇺🇸
St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States
🇺🇸Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 51
- Registration Number
- NCT01115517
- Locations
- 🇺🇸
Robert Cizik Eye Clinic, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital, Houston, Texas, United States
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
- Conditions
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Cancer Research Campaign Clinical Trials Centre
- Target Recruit Count
- 242
- Registration Number
- NCT01094964
- Locations
- 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧South Manchester University Hospital, Manchester, England, United Kingdom
🇬🇧University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT01042041
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT01017640
- Locations
- 🇺🇸
Georgetown Cancer Treatment Center, Georgetown, Kentucky, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01011010
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 235
- Registration Number
- NCT01004978
- Locations
- 🇺🇸
Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 37
- Registration Number
- NCT00981656
- Locations
- 🇺🇸
Barberton Citizens Hospital, Barberton, Ohio, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 21
- Registration Number
- NCT00967291
- Locations
- 🇮🇹
Istituto Scientifico H. San Raffaele, Milan, Italy
Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae
- Conditions
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Karnataka Institute of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00966056
- Locations
- 🇮🇳
Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.